MedTrace Logo

Role of Strontium Ranelate in Proximal Femur Fragility Fractures.

NCT05712616 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-02-03

No results posted yet for this study

Summary

This study is being conducted with the aim of comparing the time to bone healing after surgery for fragility fractures of proximal femur between patients receiving strontium ranelate and placebo. Patients recruited are of 60 years of age and above. Bone healing will be assessed on clinical parameters when patient is able to ambulate full weight bearing without pain and on Xray images using RUSH score. Moreover Dexa scan will be performed pre-operatively and at 3 months postoperatively. The findings of this study will help in setting up guidelines for treatment of fragility proximal femur fractures in our population as there is still paucity of literature on effectiveness of strontium ranelate from our part of the world.

Conditions

  • Fragility Fracture
  • Femur; Fracture, Pertrochanteric
  • Clinical Trial

Interventions

DRUG

Strontium Ranelate

Dual mode of action, anabolic and anti-resorptive

DRUG

Lacto-N-Hexaose

Placebo look alike drug

Sponsors & Collaborators

  • AO Trauma Middle East and North Africa

    collaborator UNKNOWN

  • Aga Khan University Hospital, Pakistan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-11-30
Completion
2024-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05712616 on ClinicalTrials.gov